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Ily/M>r1<>nsion Clinical Studies
Erythrocyte Deficiency in Calpain Inhibitor
Activity in Essential Hypertension
SANDRO PONTREMOLI, EDON MELLONI, BIANCA SPARATORE,
FRANCA SALAMINO, ROBERTO PONTREMOLI, ALBERTO TIZIANELLO,
CRISTINA BARLASSINA, DANIELE CUSI, ROBERTO COLOMBO,
AND GIUSEPPE BIANCHI
SUMMARY The calpain-calpain inhibitor system was evaluated in erythrocytes of patients with
essential hypertension and normotensive controls, either with or without a family history of hypertension.
Calpain levels were similar in the controls and hypertensive patients, whereas the inhibitor activity level
was significantly reduced in the latter (301.8 ± 26.4 vs 220 ± 14 U/mg hemoglobin, p < 0.001). Borderline
hypertensive patients and a few controls with a history of hypertension showed low inhibitor activity.
Similar results have recently been reported in genetically hypertensive rats of the Milan strain. A
significant inverse correlation (r = —0.43, p < 0.001) was found between mean arterial pressure and
calpain inhibitor. Although the pathophysiotogical significance of these observations is not yet dear, they
suggest a new area of investigation Into the molecular mechanisms underlying essential hypertension and
its complications. (Hypertension 12: 474-478, 1988)
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THE biochemical mechanisms underlying boththe pathogenesis of essential hypertensionand the high frequency of associated organ
lesions are poorly understood. Previous studies
have shown that erythrocytes from spontaneously
hypertensive rats of the Milan strain1 have similar
amounts of the neutral Ca2+-dependent proteinase
calpain and 10 times less activity of its natural
inhibitor,2-3 as compared with normotensive rats.
Similar results were also obtained by measuring
calpain and its inhibitor activity in renal tissues
from the same rat strain.4 These data suggest that,
both in erythrocytes and kidney, calpain has lost at
least part of the components of its regulatory sys-
tem. Calpain specifically degrades membrane-
bound cytoskeletal proteins (i.e., membrane-bound
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protein kinase C, epidermal growth factor, adrener-
gic receptors, actin binding proteins, neurofilament-
associated and microtubular-associated proteins,
and a few soluble proteins).3 Based on this speci-
ficity, it may be postulated that calpain is involved
in signal transduction and processes controlling
cellular volume, shape, and deformability. Some of
the cellular abnormalities observed in hypertensive
rats and in patients with essential hypertension6-12
may be attributed to the action of an uncontrolled or
less regulated calpain activity in the cell.
In the present study, we found that the level of
calpain inhibitor in red blood cells from patients
with essential hypertension is decreased in compar-
ison with that found in normotensive subjects.
Moreover, a significant inverse correlation between
calpain inhibitor levels and mean arterial pressure
(MAP) was observed.
Subjects and Methods
Four groups of subjects were studied: Group 1 was
composed of 23 normotensive subjects without a
family history of hypertension; Group 2 was com-
posed of 17 normotensive subjects with at least one
hypertensive parent; Group 3 was composed of 19
patients with borderline hypertension; and Group 4
was composed of 49 patients with established hyper-
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tension. Hypertensive patients were recruited in the
outpatient clinics of the Institute of Medical Science,
University of Milan, or the Division of Nephrology,
Scientific Institute of Internal Medicine, University
of Genoa. The same criteria were applied for exclud-
ing secondary hypertension in both institutions. All
patients underwent routine biochemical analyses of
blood and urine, including plasma renin activity and
urinary aldosterone. Further investigations were per-
formed only when abnormalities were found in these
analyses or when other symptoms or signs sugges-
tive of secondary hypertension were present. None
of the patients were on drug treatment at the time of
the study. They either had never been treated for
hypertension or, because hypertension was so mild,
had been taken off therapy at least 4 months before
the study. Subjects in Groups 1 and 2 were recruited
in both clinics from the laboratory or medical staff or
from epidemiological studies that were in progress.
Normotensive subjects had a systolic blood pres-
sure of 140 mm Hg or less and a diastolic blood
pressure of 90 mm Hg or less in the three visits
preceding the study. Patients with borderline hyper-
tension were those with at least a normal value of
blood pressure in one of the three different measure-
ments. The family history was assessed by one of us
or by the family physician, who measured the blood
pressure of the parents on at least one occasion.
Blood samples used for the present study were
collected from an antecubital vein after a 12- to
14-hour overnight fast.
Chemicals
l25I-labeled sodium (100 mCi/ml) was obtained
from Amersham (Arlington Heights, IL, USA). Bovine
serum albumin and reagents for hemoglobin (Hb)
determination were purchased from Sigma Chemical
(St. Louis, MO, USA). Diethylaminoethyl cellulose
(DE 52) was obtained from Whatman (Clifton, NJ,
USA), and Ultrogel and AcA34 were obtained from
LKB (Bromma, Sweden). Human acid denatured
globin was prepared as described elsewhere.13 Cal-
pain was purified from human erythrocytes and
assayed as previously reported.14 The specific activ-
ity of the purified enzyme was 600,000 U/mg. One
unit of enzyme activity was defined as the amount
causing the release of 1 nmol of amino group per
hour in the assay conditions.
Assay of Calpain Inhibitor Activity
Packed red blood cells (2 ml), deprived of leuko-
cytes and platelets,14 were lysed, and the cytosolic
fractions were obtained as previously described.2 An
aliquot containing 200 mg of Hb was submitted to
diethylaminoethyl ion-exchange chromatography.2
Samples (50 yA) of the eluted fractions were heated at
90 °C for 3 minutes and assayed for calpain inhibitor
activity, as reported elsewhere.15 The total amount of
calpain inhibitor was calculated from the area under
the eluted peak. One unit of inhibitor was defined as
the amount inhibiting 1 unit of calpain activity.
Preparation of Anticalpain Monoclonal Antibody
Monoclonal anticalpain antibody was prepared as
described elsewhere.16
Radioimmunoassay for Human Erythrocyte Calpain
Purified calpain was labeled with I23I as reported
by Krantz et al.17 The specific radioactivity was 12
x 103 dpm/ng of calpain. Iodinated calpain (10 ng)
was incubated in 0.3 ml of 20 mM sodium phosphate
buffer, pH 7.5, containing 2 mM NaN3, 1 mM
EDTA, and 0.2 mg of bovine serum albumin
(Medium A) in the presence of 18 ng of MoAb c
56.3 and 20,40, or 60 fi\ of the erythrocyte cytosolic
fraction containing 15 mg/ml Hb. Each determina-
tion was performed in triplicate. The incubation
mixtures were rotated end over end at 4 °C for 20
hours, then 10 fil of antiserum (66 mg/ml) to mouse
IgG was added. After 2 hours at 20 °C, the mixtures
were centrifuged at 1000 g for 10 minutes. The
precipitates were washed three times with 1 ml
of Medium A and counted in a Packard gamma
counter (Downers Grove, IL, USA).
Blood Chemistry Tests
Creatinine, urea, electrolytes and other standard
blood chemistry evaluations were performed on
serum according to routine methods.
Statistical Analysis
Statistical analysis was performed using the
SPSSPC+ package (Chicago, IL, USA) on an AT
IBM personal computer (Armonk, NY, USA). The
analysis used was one-way analysis of variance with
the multiple a posteriori comparison Student-
Newman-Keuls and least significant difference tests
and simple and multiple linear regression analyses.
Results
Major clinical data of the four groups of subjects
are reported in Table 1. Serum levels of sodium and
potassium, uric acid, creatinine clearance, and body
size indexes were similar in the four groups, whereas
the mean age and blood pressure were significantly
different. Calpain inhibitor activity in the erythro-
cytes is shown in Figure 1. The mean values (±SD)
of inhibitor activity were 301.8 ± 26.4 U/mg Hb in
Group 1, 273 ± 60 U/mg Hb in Group 2, 222 ± 71 U/
mg Hb in Group 3, and 220 ± 14 U/mg Hb in Group
4, with wide overlapping of the individual values
among the four groups. As calpain inhibitor corre-
lated negatively with age (r = -0.26, p = 0.007) and
mean age values were different in the four groups
(see Table 1), the residuals of the regression of
calpain inhibitor with age were used for comparison
among the groups. The one-way analysis of vari-
ance with the a posteriori comparison Student-
Newman- Keuls test of the residuals of calpain inhib-
itor with age was significantly different (p < 0.05) in
Group 1, as compared with the other three groups.
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TABLE 1. Clinical Characteristics of the Subjects
Variables
Age (yr)
Weight (kg)
Height (cm)
Quetelet index (weight/height2)
MAP (mm Hg)
Uric acid (mg/dl)
Creatinine clearance (ml/min)
Serum sodium (mEq/L)
Serum potassium (mEq/L)
Group 1
(n = 23)
30.9±11.7*
66.3±15
167±9
23±4
93.9±4.8*
5.1 ±0.7
128.1 ±44.5
138.2±2.7
4.13±0.05
Group 2
(n= 17)
23.5±9*
66.5±14
167±3
23±4
91.7±7.5*
4.5±1.14
135.9±45.9
136.5±1.7
4.24+0.47
Group 3
(n = 19)
30.5±10*
75.2±17
173±9
25±5
106.4±5.1
4.9+0.86
136.2±38.0
139.9+2.9
4.4±0.48
Group 4
(n = 49)
42.1±11
72.2±13
170±9
25±4
121.1±9.9t, t
5.01±1.27
134.8±45.7
141.0±10.0
4.25±0.48
Values are means ± SD. Group 1 = normotensive subjects with no family history of hypertension; Group 2 =
normotensive subjects with a family history of hypertension; Group 3 = borderline hypertensive patients; Group 4
= essential hypertensive patients.
All statistical comparisons were by one-way analysis of variance.
*p < 0.05, compared with Group 4 values,
tp < 0.05, compared with Group 2 values.
Xp < 0.05, compared with Group 1 values.
The backward multiple regression analysis, per-
formed on calpain inhibitor with MAP and age as
independent variables, showed that the only signif-
icant variable was MAP (r = -0.43, p < 0.001). The
determination coefficient (r2) decreased from 19.1%
to 18.8% when the contribution of age was removed.
The correlation of calpain inhibitor with MAP is
shown in Figure 2.
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FIGURE 1. Distribution of calpain inhibitor values in the
four groups studied. Group 1 = normotensive subjects
with no family history of hypertension; Group 2 = nor-
motensive subjects with a family history of hypertension;
Group 3 = borderline hypertensive patients; Group 4 =
hypertensive patients; Hb = hemoglobin, p < 0.001,
Group 1 versus Groups 3 and 4 (by one-way analysis of
variance with least significant difference test).
The mean levels of calpain in the erythrocytes of
Groups 1, 3, and 4 were similar (81 ±11.4 ng/mg
Hb in Group 1, 82 ± 11.2 ng/mg Hb in Group 3, and
80.5 ±11.2 ng/mg Hb in Group 4; Figure 3).
Discussion
A number of mechanisms that reduce the Ca2+
requirement of calpain to close to the physiological
range have been identified.18 Exposure to Ca2+ and
substrate, such as human globin, or binding to the
inner face of the erythrocyte membrane produces a
rapid autoproteolytic conversion of the native cal-
pain to a smaller form with an approximately 200
times lower Ca2+ requirement. This process is reg-
ulated by the presence in the cell of a natural
inhibitor that blocks the catalytic activity as well as
the autoproteolytic activation of calpain.14 In this
study we found that, whereas the erythrocyte levels
of calpain were similar in normotensive and hyper-
tensive subjects, the calpain inhibitor activity was
significantly reduced in the erythrocytes of a large
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FIGURE 2. Correlation between MAP and calpain inhib-
itor for the total population. Hb = hemoglobin.
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FIGURE 3. Distribution of calpain levels in 23 normo-
tensive subjects with no family history of hypertension
(Group I), 7 borderline hypertensive patients (Group 3), and
26 hypertensive patients (Group 4). Hb = hemoglobin.
number of patients with essential hypertension.
Low values of inhibitor were also found in subjects
with borderline hypertension as well as in a few
normotensive subjects with a family history of
hypertension. These data demonstrate the exis-
tence of an altered calpain-calpain inhibitor system
in the erythrocytes of patients with essential hyper-
tension. Interestingly, similar abnormalities have
also been found in both erythrocytes and renal
tissue of genetically hypertensive rats of the Milan
strain, which show other similarities with human
essential hypertension.'-4 It is therefore reasonable
to speculate that reduced levels of calpain inhibitor
also may occur in human tissues other than red
blood cells, including the kidney. Furthermore, low
levels of calpain inhibitor were also observed in a
few Group 2 subjects, and one-way analysis of
variance showed that Group 2 did not differ statis-
tically from Groups 3 or 4. Accordingly, it seems
unlikely that decreased inhibitor levels are a conse-
quence of the hypertensive state.
It may be hypothesized that the negative correla-
tion between calpain inhibitor levels and blood
pressure is due to a common factor influencing both
these variables independently. Alternatively, the
reduction of calpain inhibitor activity could be a
biochemical abnormality directly related to the
genetic mechanisms underlying hypertension that
trigger the subsequent sequence of biochemical,
cellular, and organ dysfunctions responsible for the
blood pressure rise. Data have not yet been reported
that support one rather than the other of these
hypotheses. However, since it has been shown that
calpain is involved in receptor turnover and binding,3
(including the adrenergic receptor19), protein kinase
C activation, and modification of the protein com-
position of the membrane skeleton,3 and it has been
suggested that active ion transport across the renal
tubules could be influenced by this enzyme,20 the
relation between calpain inhibitor and blood pres-
sure may be mediated through one of these mech-
anisms. A synthetic calpain inhibitor of bovine
cardiac muscle calpain has the ability to reduce
experimental myocardial infarction size in vivo.21
This finding suggests that calpain or other thiolpro-
teinases have a role in myocardial necrosis. It is
now widely recognized that normalization of blood
pressure with antihypertensive therapy produces
only minor changes in the incidence of cardiac
disease, which on the other hand is directly corre-
lated with blood pressure in the unselected pop-
ulation.22- a This discrepancy might be explained by
postulating that a rise in blood pressure and decrease
in calpain inhibitor are somehow associated in the
same patient by pleiotropic or linkage mechanisms.
Antihypertensive therapy could leave unmodified
the low levels of inhibitor; thus, any increase in
cytosolic calcium, which may occur after hypoxia
and ischemia,24 may produce more tissue damage in
hypertensive subjects because of a more facilitated
activation of calpain.
The results obtained in the present study do not
shed light on the possible pathophysiological role
played by a modified calpain-calpain inhibitor sys-
tem in essential hypertension. However, they sug-
gest a new area of research aimed at clarifying the
molecular mechanisms underlying the development
of essential hypertension or those responsible for
organ lesions accompanying this disease.
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